BPC-157 + TB-500 Stack

BPC-157 and TB-500 are both healing peptides, but they work through entirely different pathways—making them ideal stack partners:

• BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor receptors, and modulates nitric oxide for localized healing.
• TB-500 upregulates actin, a protein essential for cell migration and proliferation. It also has potent anti-inflammatory and anti-fibrotic properties.

Together, BPC-157 builds the blood supply to damaged tissue while TB-500 mobilizes repair cells to the area. The synergy is why this stack has become the default protocol for injury recovery in peptide research.

This is a two-peptide stack—simple and effective:

• BPC-157 — Administer subcutaneously as close to the injury as possible for best results. Alternatively, intramuscular injection is acceptable. Systemic (abdominal) injection provides whole-body benefits.
• TB-500 — Administered subcutaneously anywhere on the body. TB-500 is systemic by nature—it doesn't need to be injected near the injury site due to its cell-migration mechanism.

These two peptides can be mixed in the same syringe for a single injection if desired, though many researchers prefer separate administrations.

The loading phase for TB-500 is important—it saturates the tissue with thymosin beta-4 fragments to jumpstart repair. BPC-157 dosing remains consistent throughout. Total protocol duration: 4–8 weeks depending on injury severity.

Days 3–7: Pain and inflammation begin decreasing. Many subjects report noticeable pain reduction within the first week. Swelling around injuries diminishes.

Weeks 2–4: Active healing phase. Range of motion improves. Partial tendon and muscle tears show significant repair. Chronic nagging injuries that persisted for months begin resolving.

Weeks 4–8: Structural healing solidifies. Ligament and tendon injuries show imaging-confirmed improvement. Many subjects report full resolution of injuries that failed to heal through conventional rest and physical therapy alone.

Both peptides have strong safety profiles. BPC-157, derived from human gastric juice proteins, shows essentially no toxicity in research. TB-500 may cause occasional lethargy, head rushes, or mild flu-like symptoms during the loading phase as the body mounts a stronger repair response.

Precautions: Avoid this stack if you have active cancer—both peptides promote angiogenesis and cell proliferation. If recovering from surgery, wait until your surgeon clears you. Infection at the injection site should be resolved before continuing.

The BPC-157/TB-500 stack requires high-purity compounds to work effectively. We trust Ascension Peptides for both:

• 99%+ purity verified by third-party HPLC testing
• Properly lyophilized for maximum shelf stability
• Clear reconstitution and storage instructions included

Ascension Peptides provides the quality assurance that makes the difference between a protocol that works and one that wastes your time.